A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Ifinatamab deruxtecan
DRUG: Topotecan
DRUG: Amrubicin
DRUG: Lurbinectedin

Sponsor

Daiichi Sankyo

Collaborators

[object Object]